Neuro-oncology advances最新文献

{"title":"Characterizing long- and short-survival glioblastoma patients with FLT-PET/MRI and metabolomics.","authors":"Jan Axelsson, Benny Björkblom, Thomas Asklund, Jens Brandel, Svante Larhed, Gabriela M Ringmar, Karolina Hedman, Katrine Riklund, Rickard L Sjöberg, Maria Sandström","doi":"10.1093/noajnl/vdaf034","DOIUrl":"https://doi.org/10.1093/noajnl/vdaf034","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma is the most aggressive and malignant brain tumor, characterized by a high degree of heterogeneity, invasiveness, and resistance to treatment. Patients with glioblastoma have a very poor prognosis despite multimodal interventions. In this study, we investigated how ¹⁸F-fluorothymidine (¹⁸F-FLT) PET combined with contrast-enhanced MRI and blood metabolomics can contribute to evaluate prognosis and treatment response for patients with glioblastoma.</p><p><strong>Methods: </strong>Patients, scheduled for surgery due to suspected high-grade glioma were included in this clinical study and underwent four ¹⁸F-FLT-PET/MRI examinations prior to surgery and during standard treatment. Blood samples were collected and analyzed by metabolomics. Patients were grouped according to survival as long-time survivors (>3 years) and short-time survivors (<500 days).</p><p><strong>Results: </strong>Both 2 and 6 weeks into treatment, short-time survivors displayed a significantly larger tumor volume than long-time survivors. When comparing MRI findings during treatment, long-time survivors displayed a substantial tumor decrease, whereas the short-time survivors showed minor or no effect. Regarding ¹⁸F-FLT-PET the results were not as unambiguous. Furthermore, there was a clear and significant separation in the metabolomic pattern in blood between the survival groups and across treatment time points.</p><p><strong>Conclusions: </strong>MRI measures of tumor volume and growth during treatment appear to be prognostic clinical factors that affect outcome. Metabolomic patterns in blood differ significantly between the defined survival groups and may serve as support for an early forecast of prognosis. We also observe a clear separation in metabolite levels between different time points during treatment, which likely reflects treatment effects.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf034"},"PeriodicalIF":3.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse neurologic events of immune checkpoint inhibitor monotherapy vs. combination therapy for melanoma.","authors":"Nikita Das, Ravi Dhamija, David C Kaelber, Michael Kelly, Peter Xie, Deven Reddy","doi":"10.1093/noajnl/vdaf030","DOIUrl":"https://doi.org/10.1093/noajnl/vdaf030","url":null,"abstract":"<p><strong>Background: </strong>Over the past decade, novel immune checkpoint inhibitors have revolutionized melanoma treatment. These new therapies are associated with complex immune-related adverse events. This study examines whether combination anti-PD-1/CTLA-4 immunotherapy for melanoma is associated with increased incidence of neurologic irAEs (n-irAEs) compared to anti-PD-1 monotherapy.</p><p><strong>Methods: </strong>A retrospective, multicenter study using TriNetX identified adult melanoma patients receiving anti-PD-1 monotherapy (pembrolizumab or nivolumab) (Cohort 1: <i>n</i> = 10,586) and patients receiving anti-PD-1/CTLA-4 combination therapy (nivolumab + ipilimumab) (Cohort 2: <i>n</i> = 5,705). Propensity score matching generated final cohorts (<i>n</i> = 5,185) using covariates: gender, race, age at diagnosis, TNM staging, nervous system metastasis, and history of neurologic disease. Odds ratios (OR) for n-irAE subtypes at 3- and 5-year post-therapy initiation were calculated, and Kaplan-Meier analyses assessed overall survival by aggregate n-irAE status in each cohort.</p><p><strong>Results: </strong>At 3 years, patients receiving combination immunotherapy exhibited increased risk of immune-related meningitis (OR: 2.6, 95% CI: [1.7, 4.1]) and encephalitis (OR: 3.0, 95% CI: [1.9, 4.9]), peripheral neuropathy (OR: 1.3, 95% CI [1.1, 1.5]), and myopathy (OR: 1.5, 95% CI: [1.1, 2.1]), but no significantly increased risk of demyelinating syndromes (OR: 1.5, 95% CI: [0.82, 2.6]), vasculitis (OR: 0.88, 95% CI: [0.43, 1.8]), or neuromuscular junction disorders (OR: 1.3, 95% CI: [0.87, 2.0]). At 5 years, these trends for risk of neurologic irAEs persisted. There was no significant difference in overall survival by n-irAE presence at 3 or 5 years in either cohort.</p><p><strong>Conclusions: </strong>Melanoma patients receiving combination anti-PD-1/CTLA-4 immunotherapy have greater long-term risk of n-irAEs than patients receiving anti-PD-1 monotherapy.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf030"},"PeriodicalIF":3.7,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial extranodal marginal zone lymphoma mimicking meningioma: A rare but insidious entity.","authors":"Marta Bonada, Giacomo Baso, Daniele Lorenzini, Gianluca Marucci, Antonio Silvani, Francesco DiMeco, Massimiliano Del Bene","doi":"10.1093/noajnl/vdaf031","DOIUrl":"https://doi.org/10.1093/noajnl/vdaf031","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf031"},"PeriodicalIF":3.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear NAD⁺ synthase nicotinamide mononucleotide adenylyltransferase 1 contributes to nuclear atypia and promotes glioma growth.","authors":"Jiaqi Liu, Yi Zhu, Tijana Canic, Zoraida Diaz-Perez, Sakir Humayun Gultekin, R Grace Zhai","doi":"10.1093/noajnl/vdaf029","DOIUrl":"https://doi.org/10.1093/noajnl/vdaf029","url":null,"abstract":"<p><strong>Background: </strong>Glioma is a malignant primary brain tumor with a poor prognosis and short survival. NAD⁺ is critical for cancer growth; however, clinical trials targeting NAD⁺ biosynthesis had limited success, indicating the need for mechanistic characterization. Nuclear atypia, aberrations in the size and shape of the nucleus, is widely observed in cancer and is often considered a distinctive feature in diagnosis; however, the molecular underpinnings are unclear.</p><p><strong>Methods: </strong>We carried out high-resolution immunohistochemical analyses on glioma tissue samples from 19 patients to analyze the expression of NAD⁺ synthase nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), and its correlation with nuclear atypia in gliomas. Utilizing a <i>Drosophila</i> model of glial neoplasia, we investigated the genetic role of nuclear NMNAT in glioma growth in vivo, elucidating the cellular mechanisms of NMNAT1 in promoting nuclear atypia and glioma growth.</p><p><strong>Results: </strong>In low-grade glioma and glioblastoma, a higher transcription level of NMNAT1 is correlated with poorer disease-free survival. Samples of high-grade gliomas contained a higher percentage of glial cells enriched with NMNAT1 protein. We identified a specific correlation between nuclear NMNAT1 protein level with nuclear atypia. Mechanistic studies in human glioma cell lines and in vivo <i>Drosophila</i> model suggest that NMNAT1 disrupts the integrity of the nuclear lamina by altering the distribution of lamin A/C and promotes glioma growth.</p><p><strong>Conclusions: </strong>Our study uncovers a novel functional connection between the NAD⁺ metabolic pathway and glioma growth, reveals the contribution of the NAD⁺ biosynthetic enzyme NMNAT1 to nuclear atypia, and underscores the role of nuclear NMNAT1 in exacerbating glioma pathology.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf029"},"PeriodicalIF":3.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism incidence shortens survival in isocitrate dehydrogenase wild-type glioblastoma.","authors":"Anthony R Sloan, Alan J Gordillo, Austin Kennemer, Alok A Khorana, Craig Horbinski, David C Kaelber, Scott J Cameron, Justin D Lathia","doi":"10.1093/noajnl/vdaf018","DOIUrl":"https://doi.org/10.1093/noajnl/vdaf018","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf018"},"PeriodicalIF":3.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Size matters: Early progression of melanoma brain metastases after treatment with immune checkpoint inhibitors.","authors":"Sophie H A E Derks, Li Shen Ho, Stephan R Koene, Martijn P A Starmans, Esther Oomen-de Hoop, Arjen Joosse, Maja J A de Jonge, Kishan A T Naipal, Joost L M Jongen, Martin J van den Bent, Marion Smits, Astrid A M van der Veldt","doi":"10.1093/noajnl/vdaf026","DOIUrl":"10.1093/noajnl/vdaf026","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) are effective treatments for patients with metastatic melanoma, including patients with brain metastasis (BM). However, half of patients with melanoma BM have intracranial progression within 6 months after the start of ICIs. We investigated whether size affects response to ICIs in patients with melanoma BM.</p><p><strong>Methods: </strong>In this single-center cohort study, patients with melanoma BM who were treated with ICIs between 2012 and 2021 were included. Clinical and radiologic features were collected at baseline. Longest axial diameter of all BMs was measured on baseline and follow-up MRI, and segmentation was performed for all BMs on baseline MRI. Lesion-level logistic regression analysis and patient-level survival analysis were performed for early BM progression (ie, within 6 months after start of ICIs) and intracranial progression-free survival (PFS), respectively.</p><p><strong>Results: </strong>A total of 82 patients were included with a total of 464 BMs. At baseline, 37.8% of patients had ≥ 4 BMs and 53.7% of patients had at least one BM with a diameter ≥ 10 mm. In multivariable analysis on the lesion level, baseline BM diameter was associated with early BM progression (odds ratio 1.10, 95%CI 1.05-1.15, <i>P</i> < .001). On the patient level, having at least one BM ≥ 10mm was associated with shorter intracranial PFS (hazard ratio 2.08, 95%CI 1.64-5.56, <i>P</i> < .001).</p><p><strong>Conclusions: </strong>Large BM diameter was associated with a higher risk of early progression after the start of ICIs. Therefore, local therapy should be considered for patients who are treated with ICIs and who have melanoma BMs ≥ 10 mm.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf026"},"PeriodicalIF":3.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by <i>O</i>-(2-[¹⁸F]fluoroethyl)-l-tyrosine PET.","authors":"Michel Friedrich, Jan-Michael Werner, Joachim P Steinbach, Michael Sabel, Ulrich Herrlinger, Marc Piroth, Gabriele Stoffels, Christian P Filss, Philipp Lohmann, Nadim J Shah, Maximilian I Ruge, Felix M Mottaghy, Roland Goldbrunner, Karl-Josef Langen, Gereon R Fink, Martin Kocher, Norbert Galldiks","doi":"10.1093/noajnl/vdaf023","DOIUrl":"10.1093/noajnl/vdaf023","url":null,"abstract":"<p><strong>Background: </strong>Amino acid PET using the tracer <i>O</i>-(2-[¹⁸F]fluoroethyl)-l-tyrosine (FET) is one of the most reliable imaging methods for detecting glioma recurrence. Here, we hypothesized that functional MR connectivity between the metabolic active recurrent tumor region and resting-state networks of the brain could serve as a prognostic imaging biomarker for overall survival (OS).</p><p><strong>Methods: </strong>The study included 82 patients (26-81 years; median Eastern Cooperative Oncology Group performance score, 0) with recurrent gliomas following therapy (WHO-CNS 2021 grade 4 glioblastoma, <i>n</i> = 57; grade 3 or 4 astrocytoma, <i>n</i> = 12; grade 2 or 3 oligodendroglioma, <i>n</i> = 13) diagnosed by FET PET simultaneously acquired with functional resting-state MR. Functional connectivity (FC) was assessed between tumor regions and 7 canonical resting-state networks.</p><p><strong>Results: </strong>WHO tumor grade and IDH mutation status were strong predictors of OS after recurrence (<i>P</i> < .001). Overall FC between tumor regions and networks was highest in oligodendrogliomas and was inversely related to tumor grade (<i>P</i> = .031). FC between the tumor region and the dorsal attention network was associated with longer OS (HR, 0.88; 95%CI, 0.80-0.97; <i>P</i> = .007), and showed an independent association with OS (HR, 0.90; 95%CI, 0.81-0.99; <i>P</i> = .033) in a model including clinical factors, tumor volume and MGMT. In the glioblastoma subgroup, tumor volume and FC between the tumor and the visual network (HR, 0.90; 95%CI, 0.82-0.99, <i>P</i> = .031) were independent predictors of survival.</p><p><strong>Conclusions: </strong>Recurrent gliomas exhibit significant FC to resting-state networks of the brain. Besides tumor type and grade, high FC between the tumor and distinct networks could serve as independent prognostic factors for improved OS in these patients.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf023"},"PeriodicalIF":3.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New-onset facial spasm is associated with treatment failure after radiosurgery in vestibular schwannoma.","authors":"Sophie Shih-Yüng Wang, Albertus van Eck, Georgios Naros, Gerhard Horstmann, Marcos Tatagiba","doi":"10.1093/noajnl/vdaf021","DOIUrl":"https://doi.org/10.1093/noajnl/vdaf021","url":null,"abstract":"<p><strong>Background: </strong>New-onset facial spasm (NOFS) has been reported to be a post-therapeutic side effect, when treating vestibular schwannoma (VS) with radiosurgery (SRS) and has been linked to post-treatment pseudoprogression. The aim of this study was to identify risk factors for developing NOFS after SRS treatment and to investigate NOFS as a clinical parameter for radiographic tumor response in VS.</p><p><strong>Methods: </strong>This study included all consecutive patients of <i>N</i> = 1,998 between 2004 and 2020, which were treated with SRS identified by a prospective registry. Patient and tumor characteristics (ie, sex, age, tumor extension and size, and intracanalicular extension) were analyzed retrospectively. Statistical testing was performed with R Studio.</p><p><strong>Results: </strong>The incidence of NOFS was 5% overall. In total, 62% were permanent NOFS, whereas 39% recovered spontaneously between 4 and 34 months, postinterventionally. The incidence of NOFS was unrelated to tumor volume-however, previous SRS increased the incidence of NOFS to 20%. In primary SRS therapy, facial spasm was associated with a higher recurrence rate compared to non-NOFS patients in the Kaplan-Meier analysis (<i>P</i> < 0.001). Tumor control decreased with increasing tumor size. The rate of pseudoprogression was higher in the group of transient NOFS at 39% compared to permanent NOFS at 18% (<i>P</i> = 0.032).</p><p><strong>Conclusions: </strong>The risk of NOFS was significantly higher in recurrent compared to primary treatment (20% vs 5%) and the majority of NOFS was permanent. The incidence of permanent NOFS was significantly associated with treatment failure. Temporary NOFS was associated with pseudoprogression. Future analysis comparing the risk profile of either treatment option should include facial spasm as a significant VS-related postinterventional symptom. Patients with postinterventional NOFS should be followed-up long-term for higher risk of treatment failure.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf021"},"PeriodicalIF":3.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distant brain failure after stereotactic radiosurgery for brain metastases in patients receiving novel systemic treatments.","authors":"Paul van Schie, Ruben G Huisman, Terry Wiersma, Joost L Knegjens, Edwin P M Jansen, Dieta Brandsma, Annette Compter, Philip C de Witt Hamer, René Post, Gerben R Borst","doi":"10.1093/noajnl/vdaf027","DOIUrl":"10.1093/noajnl/vdaf027","url":null,"abstract":"<p><strong>Background: </strong>Novel systemic therapies, such as immunotherapy and targeted therapies, have shown better systemic disease control in the last decennium. However, the effect of these treatments on distant brain failure (DBF) in patients with brain metastases (BM) remains a topic of discussion. Improving time to DBF leads to longer overall survival (OS), as is reflected in the brain metastasis velocity (BMV). This study presents real world data about the combined effects of local and systemic treatments on DBF and survival.</p><p><strong>Methods: </strong>A retrospective consecutive cohort study was conducted. Patients with newly diagnosed BM were included between June 2018 and May 2020. Factors associated with DBF were analyzed in multivariate models. The association between BMV and overall survival was analyzed with linear regression analysis.</p><p><strong>Results: </strong>Three hundred and three patients were included. Two hundred and sixty-two (86%) patients received stereotactic radiotherapy, 41 (14%) awaited in first instance the intracranial effect of newly started or switched systemic treatment. Median time to DBF after radiotherapy was 21 months (95% CI 15-27), median OS was 20 months (IQR 10-36). Receiving immunotherapy or targeted therapy were associated with a lower hazard of DBF, compared with chemotherapy. The presence of > 5 initial BM and progressive or stable extracranial disease were associated with increased DBF. BMV was significantly associated with overall survival.</p><p><strong>Conclusions: </strong>In this retrospective cohort, patients who received immunotherapy or targeted therapy experienced a reduced risk of DBF in comparison to those treated with chemotherapy. A higher BMV was associated with a decreased OS.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf027"},"PeriodicalIF":3.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboplatin and vinblastine monthly in the optic pathway and hypothalamic gliomas: A retrospective analysis in a single institute.","authors":"Ting-Bin Lin, Chao-Yang Kuo, Feng-Chi Chang, Shih-Chieh Lin, Yi-Wei Chen, Muh-Lii Liang, Yi-Yen Lee","doi":"10.1093/noajnl/vdaf020","DOIUrl":"10.1093/noajnl/vdaf020","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy plays an important role in the treatment of optic pathway hypothalamic gliomas (OPHGs). Commonly used regimens include carboplatin and vincristine and monotherapy with vinblastine weekly. In this retrospective study, we used a monthly regimen of carboplatin and vinblastine to treat progressive/recurrent OPHGs and evaluated their effectiveness, visual preservation, and toxicity.</p><p><strong>Methods: </strong>The study involved patients with OPGH who were treated with carboplatin and vinblastine once per month. The response, disease progression, overall survival, vision changes, and toxicity were recorded according to their medical charts at our institute, and survival was analyzed.</p><p><strong>Results: </strong>A total of 25 patients were included, including 15 males (60%) and 10 females (40%). The response rate was 11/25 (44%), and the stabilization rate (complete response rate + partial response rate + minor response rate + and stable disease rate) was 21/25 (84%). The 3-year progression-free survival (PFS) rate was 54.6%, and the 5-year PFS rate was 46.8%. The 5-year overall survival rate was 100%. There were 6 patients who showed improved visual acuity (28.6%). Stable vision was found in 52.4% of patients. Only 2 patients experienced severe allergic reactions to carboplatin.</p><p><strong>Conclusions: </strong>The results showed that extending the dosing interval of carboplatin and vinblastine to every month can be seen as a similar response compared with previous regimens. The toxicity of this regimen is milder, and patients benefit from a lower frequency of hospital visits. The regimen can be considered as a choice of the first line of chemotherapy for OPHG patients.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"7 1","pages":"vdaf020"},"PeriodicalIF":3.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}